Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 19;17(9):e0274864.
doi: 10.1371/journal.pone.0274864. eCollection 2022.

A predictor model of treatment resistance in schizophrenia using data from electronic health records

Affiliations

A predictor model of treatment resistance in schizophrenia using data from electronic health records

Giouliana Kadra-Scalzo et al. PLoS One. .

Abstract

Objectives: To develop a prognostic tool of treatment resistant schizophrenia (TRS) in a large and diverse clinical cohort, with comprehensive coverage of patients using mental health services in four London boroughs.

Methods: We used the Least Absolute Shrinkage and Selection Operator (LASSO) for time-to-event data, to develop a risk prediction model from the first antipsychotic prescription to the development of TRS, using data from electronic health records.

Results: We reviewed the clinical records of 1,515 patients with a schizophrenia spectrum disorder and observed that 253 (17%) developed TRS. The Cox LASSO survival model produced an internally validated Harrel's C index of 0.60. A Kaplan-Meier curve indicated that the hazard of developing TRS remained constant over the observation period. Predictors of TRS were: having more inpatient days in the three months before and after the first antipsychotic, more community face-to-face clinical contact in the three months before the first antipsychotic, minor cognitive problems, and younger age at the time of the first antipsychotic.

Conclusions: Routinely collected information, readily available at the start of treatment, gives some indication of TRS but is unlikely to be adequate alone. These results provide further evidence that earlier onset is a risk factor for TRS.

PubMed Disclaimer

Conflict of interest statement

RDH, HS have received research funding from Roche, Pfizer, Janssen and H Lundbeck. GKS and DFdF have received research funding from Janssen and H Lundbeck. JHM has received research funding from H Lundbeck for this study. SES is employed on a grant held by Cardiff University from Takeda for work unrelated to the analysis reported here. SRC, NB are employees of H Lundbeck. BJK is employee of Lundbeck Pharmaceuticals LLC. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Antipsychotic coding process timeline for coding outcome data.
Fig 2
Fig 2. Kaplan-Meier curve of the survival probability for treatment resistant schizophrenia.
Fig 3
Fig 3. Nomogram for Cox Lasso regression to calculate individual normalized prognostic indexes (PI, given by the linear predictor line) for treatment resistant schizophrenia.
Coefficients are based on the Lasso Cox model.—To predict the rate of survival using the nomogram, one can take the example of a 30-year-old patient, with Schizophrenia, having 34 inpatient days recorded at 3 months before the 1st antipsychotic (AP) date, 50 inpatient days recorded 3 months after 1st AP date, 15 community face-to-face days recorded 3 months before 1st AP date, having a minor problem requiring no action and having mood disorders as comorbidity, has a total point score of 78 + 33 + 28 + 6 + 18 + 10 + 0 = 173. This corresponds to a normalized prognostic index of 0.57 (linear predictor line) for TRS, meaning that the patient has a probability to become TRS at 1 year falling in the range 4.14%-7.66%, at 2 years falling in the range 7.62%-13.89%, at 5 years in the range 16.45%-28.74% and at 10 years in the range 26.57%-44.13% (see S3 Table).

References

    1. Demjaha A, Lappin JM, Stahl D, et al.. Antipsychotic treatment resistance in first-episode psychosis: Prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981–1989. doi: 10.1017/S0033291717000435 - DOI - PubMed
    1. Lally J, Gaughran F. Treatment resistant schizophrenia—Review and a call to action. Ir J Psychol Med. 2019;36(4):279–291. doi: 10.1017/ipm.2018.47 - DOI - PubMed
    1. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: A systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. doi: 10.1097/YIC.0b013e32836508e6 - DOI - PubMed
    1. Shah P, Iwata Y, Brown EE, et al.. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):11–22. doi: 10.1007/s00406-019-01053-6 - DOI - PubMed
    1. Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study. Psychiatry Res. 2017;250(May 2016):65–70. doi: 10.1016/j.psychres.2017.01.064 - DOI - PubMed

Publication types

Substances